Wednesday, April 10, 2024
MOLLI Surgical is pioneering a new era in minimally invasive breast surgery with the introduction of OncoPen™. This innovative surgical tool, resembling a sleek pen, seamlessly integrates with the renowned MOLLI® 2 System. It offers surgeons advanced capabilities for precise targeting and removal of cancerous lesions, marking a significant progression in minimally invasive breast surgery.
OncoPen sets itself apart from traditional techniques by eliminating the need for wires, providing surgeons with greater flexibility in scheduling and enhancing the overall patient experience. The procedure involves placing a tiny MOLLI® Marker near the tumor before surgery. During the procedure, real-time 3D guidance on the MOLLI® Tablet directs the surgeon to the exact location of the lesion, allowing for targeted removal with minimal disruption to healthy tissue and potentially improving cosmetic outcomes.
The pen-like design of OncoPen seamlessly integrates into existing surgical workflows, enhancing the capabilities of the MOLLI 2 System. Surgeons express confidence in their ability to achieve precise outcomes, enabling them to deliver effective and compassionate care to patients.
With the increasing prevalence of breast cancer, there is a growing demand for minimally invasive surgical techniques that prioritize patient comfort and outcomes. OncoPen, designed to work with the advanced navigation features of the MOLLI 2 System, addresses this demand and represents a significant advancement in MOLLI Surgical's commitment to improving surgical precision while prioritizing patient well-being.
Source: prnewswire.com
